Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis

被引：8
作者：
Bourdette, Dennis [1 ,2 ]
Hartung, Daniel [3 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA
[2] Vet Affairs Portland Hlth Care Syst, Multiple Sclerosis Ctr Excellence West, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Portland, OR 97201 USA
来源：
JAMA NEUROLOGY | 2015年 / 72卷 / 12期
关键词：
TRIAL; MULTICENTER; COPAXONE(R); COP-1; DRUGS;
D O I：
10.1001/jamaneurol.2015.2605
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1411 / 1413
页数：4
相关论文
共 50 条
  • [41] Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate
    Williams, Mitzi J.
    Johnson, Kristen
    Trenz, Helen M.
    Korrer, Stephanie
    Halpern, Rachel
    Park, Yujin
    Herrera, Vivian
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (01) : 107 - 115
  • [42] Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
    Khan, Omar
    Rieckmann, Peter
    Boyko, Alexey
    Selmaj, Krzysztof
    Ashtamker, Natalia
    Davis, Mat D.
    Kolodny, Scott
    Zivadinov, Robert
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (06) : 818 - 829
  • [43] Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States
    Hernandez, Luis
    Guo, Shien
    Kinter, Elizabeth
    Fay, Monica
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 684 - 695
  • [44] Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
    Arnold, Douglas L.
    Narayanan, Sridar
    Antel, Samson
    [J]. JOURNAL OF NEUROLOGY, 2013, 260 (07) : 1901 - 1906
  • [45] The effectiveness of glatiramer acetate in clinical practice: an observational study
    Fernandez-Fernandez, Oscar
    Garcia-Trujillo, Lucia
    Guerrero-Fernandez, Miguel
    Leon, Antonio
    Lopez-Madrona, Jose C.
    Alonso, Ana
    Bustamante, Rafael
    Fernandez-Sanchez, Victoria E.
    [J]. REVISTA DE NEUROLOGIA, 2012, 54 (01) : 1 - 9
  • [46] Long-term effectiveness of glatiramer acetate in clinical practice conditions
    Arnal-Garcia, Carmen
    del Campo Amigo-Jorrin, Maria
    Maria Lopez-Real, Ana
    Lema-Devesa, Carme
    Llopis, Noemi
    Sanchez-de la Rosa R
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (12) : 2212 - 2218
  • [47] Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study
    Ciplea, Andrea Ines
    Kurzeja, Anna
    Thiel, Sandra
    Haben, Sabrina
    Alexander, Jessica
    Adamus, Evelyn
    Hellwig, Kerstin
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (10) : 1641 - 1650
  • [48] Generic glatiramer acetate-a step toward cheaper MS drugs?
    Sorensen, Per Soelberg
    [J]. NATURE REVIEWS NEUROLOGY, 2016, 12 (01) : 5 - 6
  • [49] Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients
    Romeo, M.
    Martinelli-Boneschi, F.
    Rodegher, M.
    Esposito, F.
    Martinelli, V.
    Comi, G.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (07) : 1060 - 1067
  • [50] Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate
    von Wyl, Viktor
    Benkert, Pascal
    Moser, Andre
    Lorscheider, Johannes
    Decard, Bernhard
    Hanni, Peter
    Lienert, Carmen
    Kuhle, Jens
    Derfuss, Tobias
    Kappos, Ludwig
    Yaldizli, Ozgur
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 439 - 448
12345